Principal Financial Group Inc. Reduces Stake in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA)
Principal Financial Group Inc. Reduces Stake in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA)
Principal Financial Group Inc. lowered its holdings in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA – Get Rating) by 4.8% in the 1st quarter, according to the company in its most recent filing with the SEC. The firm owned 400,524 shares of the biopharmaceutical company's stock after selling 20,099 shares during the quarter. Principal Financial Group Inc. owned approximately 0.71% of Vanda Pharmaceuticals worth $4,530,000 at the end of the most recent quarter.
据信安金融集团在提交给美国证券交易委员会的最新文件中称,该公司在第一季度减持了4.8%的万达制药股份。该公司在本季度出售了20,099股后,拥有400,524股这家生物制药公司的股票。截至最近一个季度末,信安金融集团持有万达制药约0.71%的股份,价值453万美元。
Several other institutional investors and hedge funds have also bought and sold shares of the business. Comerica Bank lifted its holdings in Vanda Pharmaceuticals by 2.5% in the 1st quarter. Comerica Bank now owns 47,706 shares of the biopharmaceutical company's stock worth $537,000 after buying an additional 1,180 shares during the period. ProShare Advisors LLC lifted its holdings in Vanda Pharmaceuticals by 6.0% in the 4th quarter. ProShare Advisors LLC now owns 21,558 shares of the biopharmaceutical company's stock worth $337,000 after buying an additional 1,214 shares during the period. Gotham Asset Management LLC lifted its holdings in Vanda Pharmaceuticals by 32.8% in the 4th quarter. Gotham Asset Management LLC now owns 18,994 shares of the biopharmaceutical company's stock worth $298,000 after buying an additional 4,695 shares during the period. Nisa Investment Advisors LLC lifted its stake in shares of Vanda Pharmaceuticals by 134.6% in the 1st quarter. Nisa Investment Advisors LLC now owns 8,540 shares of the biopharmaceutical company's stock valued at $97,000 after purchasing an additional 4,900 shares during the period. Finally, Victory Capital Management Inc. lifted its stake in shares of Vanda Pharmaceuticals by 2.0% in the 4th quarter. Victory Capital Management Inc. now owns 260,687 shares of the biopharmaceutical company's stock valued at $4,090,000 after purchasing an additional 5,202 shares during the period. Hedge funds and other institutional investors own 97.25% of the company's stock.
其他几家机构投资者和对冲基金也买卖了该公司的股票。Comerica银行在第一季度增持了2.5%的万达制药股份。Comerica银行现在持有这家生物制药公司47,706股股票,价值537,000美元,在此期间又购买了1,180股。ProShare Advisors LLC在第四季度增持了6.0%的万达制药股份。ProShare Advisors LLC现在拥有这家生物制药公司21,558股股票,价值337,000美元,在此期间又购买了1,214股。Gotham Asset Management LLC在第四季度增持了32.8%的万达制药股份。Gotham Asset Management LLC现在拥有这家生物制药公司18,994股股票,价值29.8万美元,在此期间又购买了4,695股。NISA Investment Advisors LLC在第一季度增持了134.6%的万达制药股份。NISA Investment Advisors LLC现在持有这家生物制药公司8,540股股票,价值97,000美元,在此期间又购买了4,900股。最后,胜利资本管理公司在第四季度增持了万达制药2.0%的股份。胜利资本管理公司现在拥有260,687股这家生物制药公司的股票,价值4,090,000美元,在此期间又购买了5,202股。对冲基金和其他机构投资者持有该公司97.25%的股票。
Analysts Set New Price Targets
分析师设定新的价格目标
Separately, StockNews.com upgraded Vanda Pharmaceuticals from a "hold" rating to a "buy" rating in a research note on Friday, June 3rd.
另外,在6月3日周五的一份研究报告中,StockNews.com将万达制药的评级从持有上调至买入。
Insider Activity
内幕活动
Vanda Pharmaceuticals Stock Down 2.7 %
万达制药股价下跌2.7%
VNDA opened at $10.25 on Monday. The stock has a market cap of $579.75 million, a PE ratio of 51.25 and a beta of 0.47. The business has a 50 day moving average of $10.79 and a 200-day moving average of $10.92. Vanda Pharmaceuticals Inc. has a 52 week low of $9.24 and a 52 week high of $21.44.
VNDA周一开盘报10.25美元。该股市值为5.7975亿美元,市盈率为51.25倍,贝塔系数为0.47。该业务的50日移动均线切入位在10.79美元,200日移动均线切入位在10.92美元。Vanda PharmPharmticals Inc.股价52周低点为9.24美元,52周高点为21.44美元。
Vanda Pharmaceuticals Profile
万达制药简介
(Get Rating)
(获取评级)
Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs. The company's marketed products include HETLIOZ for the treatment of non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.
万达制药公司是一家生物制药公司,专注于疗法的开发和商业化,以满足高度未得到满足的医疗需求。该公司的营销产品包括用于治疗非24小时睡眠-觉醒障碍的Hetlioz;以及用于治疗精神分裂症的Fanapt口服药片。
See Also
另请参阅
- Get a free copy of the StockNews.com research report on Vanda Pharmaceuticals (VNDA)
- Why Trading Volume is Unusually High on These 3 Stocks
- Can NetApp Resume Its Rally After Strong Earnings Guidance?
- Three Reasons Why Medtronic Stock can be a Recession Winner
- Rivian Rising to the Challenge
- 3 Deflation Enablers Stocks that Can Thrive in a Recession
- 免费获取StockNews.com关于万达制药的研究报告(VNDA)
- 这三只股票的成交量为何异常高
- 在强劲的盈利指引之后,NetApp能否恢复涨势?
- 美敦力股票可以成为经济衰退赢家的三个原因
- Rivian迎接挑战
- 3通缩使能在经济衰退中蓬勃发展的股票
Want to see what other hedge funds are holding VNDA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Vanda Pharmaceuticals Inc. (NASDAQ:VNDA – Get Rating).
想看看还有哪些对冲基金持有VNDA吗?访问HoldingsChannel.com获取万达制药公司(纳斯达克代码:VNDA-GET Rating)的最新13F备案文件和内幕交易信息。
Receive News & Ratings for Vanda Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vanda Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
获得《Vanda PharmPharmticals Daily》新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收对Vanda PharmPharmticals和相关公司的最新新闻和分析师评级的每日简要摘要。